Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
29.29
-0.69 (-2.30%)
At close: Mar 5, 2026, 4:00 PM EST
28.10
-1.19 (-4.06%)
Pre-market: Mar 6, 2026, 5:27 AM EST
Enliven Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Enliven Therapeutics stock have an average target of 41, with a low estimate of 27 and a high estimate of 52. The average target predicts an increase of 39.98% from the current stock price of 29.29.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 2, 2025.
Analyst Ratings
The average analyst rating for Enliven Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $48 | Strong Buy | Maintains | $40 → $48 | +63.88% | Jul 2, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $37 | Strong Buy | Initiates | $37 | +26.32% | Jun 16, 2025 |
| Baird | Baird | Buy Maintains $40 → $52 | Buy | Maintains | $40 → $52 | +77.53% | Jun 16, 2025 |
| Jones Trading | Jones Trading | Strong Buy Maintains $36 → $27 | Strong Buy | Maintains | $36 → $27 | -7.82% | May 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $39 → $40 | Strong Buy | Maintains | $39 → $40 | +36.57% | May 15, 2025 |
Financial Forecast
Revenue This Year
7.28K
Revenue Next Year
10.20K
from 7.28K
Increased by 40.06%
EPS This Year
-2.00
from -1.83
EPS Next Year
-2.72
from -2.00
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 52,500 | 52,500 | |||
| Avg | 7,283 | 10,200 | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 620.9% | |||
| Avg | - | 40.1% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.63 | -1.63 | |
| Avg | -2.00 | -2.72 | |
| Low | -2.34 | -3.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.